Teams are getting leaner and flatter, while leaders at the top are overseeing more than ever before. Everyone, everywhere is ...

Moderna Inc. (NASDAQ:MRNA) on Tuesday released preliminary immunogenicity data for the 2025-2026 formula of Spikevax, which targets the LP.8.1 variant of SARS-CoV-2 to help prevent COVID-19. The ...

The WHO lowered its assessment from high to medium, based on several factors, including high population immunity and improved ...

Recent CDC data show that that wastewater SARS-CoV-2 detections are high and that LP.8.1 and related strains XFG and NB.1.8.1 ...

The World Health Organisation claims their roll-out prevented 14.4 million deaths worldwide in their first year, with some ...

Shares of Moderna MRNA were up 4% yesterday after the company announced positive preliminary immunogenicity data from an ...

With confusion about eligibility for COVID-19 vaccines, Gov. Gretchen Whitmer is expected to sign an executive directive ...

Moderna, Inc. (NASDAQ:MRNA) shares are up nearly 5% on Tuesday after the company announced positive preliminary ...

A two-day meeting could prove an inflection point in HHS Secretary’s Kennedy’s efforts to overhaul U.S. vaccine policy, as ...

Preliminary analysis showed the 2025-2026 formula of Spikevax generated greater than an 8-fold increase in ...

Moderna shares were down 7.4% Friday—their lowest level since March 2020. The drop brought the drugmaker’s year-to-date slump ...